Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances

  title={Expressions of ZNF436, $\beta$-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances},
  author={Zhi Chen and Na Cui and Ji-sen Zhao and Jianying Wu and Fang Ma and Cong Li and Xian-yi Liu},
  journal={European Journal of Histochemistry : EJH},
As the leading malignancy among women, breast cancer is a serious threat to the life and health of women. In this context, it is of particular importance that a proper therapeutic target be identified for breast cancer treatment. We collected the pathological tissues of 80 patients, with the view to discovering appropriate molecular targets for the treatment of breast cancer, this paper analyzes the expressions of ZNF436, β-catenin, EGFR and CMTM5 in breast cancer tissues, as well as their… 
2 Citations

Figures and Tables from this paper

Comprehensive Analysis of the Prognosis for Chemokine-Like Factor MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma
CMTMs were dramatically associated with tumor immune infiltrating cells (TIICs), but CMTM8 expression level was no significant correlations with TIICs, and GSEA results suggested that CKLF and C MTM7 participated in the development and progression of HCC accompanied with multiple biological processes.


[Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer].
The loss of CMTM5 may participate in the progression of PCa resulting from deregulated EGFR, a novel tumor suppressor and epidermal growth factor receptor in prostate cancer tissues and cells.
Reduced CMTM5 Expression Correlates With Carcinogenesis in Human Epithelial Ovarian Cancer
The reduced expression of CMTM5 correlates significantly with poorly differentiated ovarian cancer and high preoperative CA125 level and may contribute to the pathogenesis of human epithelial ovarian cancer.
CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma.
  • Jun Wu
  • Medicine, Biology
    Cancer biomarkers : section A of Disease markers
  • 2020
Examination of transcriptional and survival data of CMTMs in patients with breast carcinoma from ONCOMINE, GEPIA, Kaplan-Meier Plotter, and cBioPortal databases provided CMTM5/7 as new biomarker and prognostic factors in BC.
Association of different patterns of expression of beta-catenin and cyclin D1 with pathogenesis of breast carcinoma
An association exists between ABE and cyclin D1 in BCa and its precursor lesions implying that Wnt/beta-catenin oncogenic pathway may have a definite role in breast carcinogenesis and can be used for targeted therapy.
Bioinformatic analysis of the prognostic value of ZNF860 in recurrence-free survival and its potential regulative network in gastric cancer.
ZNF860 RNA upregulation was an independent prognostic indicator in terms of RFS in stage I/II GC and DNA CNAs and methylation alterations might collaboratively regulate ZNF860 expression.
CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis
The present data suggest that CMTM5 may function as a tumor suppressor in human RCC by suppressing the viability of RCC cells, implying its potential as a therapeutic target for this malignancy.
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.
The role of β-catenin pathway on hepatocarcinogenesis and liver cancer stem cell maintenance is reviewed and the use of small molecules targeting the Wnt/β-catanin pathway with potential application for treatment of HCC is evaluated.
Tankyrase Promotes Aerobic Glycolysis and Proliferation of Ovarian Cancer through Activation of Wnt/β-Catenin Signaling
It is found that TNKS was aberrantly overexpressed in human ovarian cancer tissues and associated with poor patient prognosis, indicating that the TNKS might serve as a potential molecular target for clinical therapy of Wnt/β-catenin dependent ovarian cancer.
The regulation of β-catenin activity and function in cancer: therapeutic opportunities
The role of β-catenin in cancer initiation, progression, dormancy, immunity and cancer stem cell maintenance is focused on, and the recent progress in the development of agents for the pharmacological modulation ofβ-Catenin activity in cancer therapy is summarized.
Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Aberrant activation of Wnt/β-catenin signaling not only regulates the development and progression of colorectal cancer, but also mediates resistance of rectal cancers to chemoradiotherapy.